FDA May Refuse Imports From Indian Drug Company RPG
The Food and Drug Administration may refuse imports of drug products manufactured at two RPG Life Sciences facilities in India, the agency said in a May 28 warning letter. An FDA inspection at the company’s facility in Navi Mumbai allegedly…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
found current good manufacturing practice violations for active pharmaceutical ingredients. An inspection of RPG’s facility in Ankleshwar found violations of CGMP for finished pharmaceuticals, FDA said.